Adjuvant efficacy of mOMV against avian influenza virus infection in mice

Byeong Jae Lee, Sang Ho Lee, Min Suk Song, Philippe Noriel Q Pascua, Hyeok il Kwon, Su Jin Park, Eun Ha Kim, Arun Decano, Se Mi Kim, Gyo Jin Lim, Doo Jin Kim, Kyu Tae Chang, Sang Hyun Kim, Young Ki Choi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 103.5 EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.

Original languageEnglish
Pages (from-to)682-688
Number of pages7
JournalJournal of Microbiology
Volume51
Issue number5
DOIs
Publication statusPublished - 2013 Oct 1
Externally publishedYes

Fingerprint

Influenza in Birds
Virus Diseases
Orthomyxoviridae
Vaccines
H5N1 Subtype Influenza A Virus
Korea
H5N2 Subtype Influenza A Virus
H9N2 Subtype Influenza A Virus
Aluminum Hydroxide
Reverse Genetics
Puerto Rico
Synthetic Vaccines
Body Weight Changes
Influenza Vaccines
Influenza A virus
Human Influenza
Birds
Antibody Formation
Chickens
Immunity

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology

Cite this

Lee, B. J., Lee, S. H., Song, M. S., Pascua, P. N. Q., Kwon, H. I., Park, S. J., ... Choi, Y. K. (2013). Adjuvant efficacy of mOMV against avian influenza virus infection in mice. Journal of Microbiology, 51(5), 682-688. https://doi.org/10.1007/s12275-013-3411-3

Adjuvant efficacy of mOMV against avian influenza virus infection in mice. / Lee, Byeong Jae; Lee, Sang Ho; Song, Min Suk; Pascua, Philippe Noriel Q; Kwon, Hyeok il; Park, Su Jin; Kim, Eun Ha; Decano, Arun; Kim, Se Mi; Lim, Gyo Jin; Kim, Doo Jin; Chang, Kyu Tae; Kim, Sang Hyun; Choi, Young Ki.

In: Journal of Microbiology, Vol. 51, No. 5, 01.10.2013, p. 682-688.

Research output: Contribution to journalArticle

Lee, BJ, Lee, SH, Song, MS, Pascua, PNQ, Kwon, HI, Park, SJ, Kim, EH, Decano, A, Kim, SM, Lim, GJ, Kim, DJ, Chang, KT, Kim, SH & Choi, YK 2013, 'Adjuvant efficacy of mOMV against avian influenza virus infection in mice', Journal of Microbiology, vol. 51, no. 5, pp. 682-688. https://doi.org/10.1007/s12275-013-3411-3
Lee, Byeong Jae ; Lee, Sang Ho ; Song, Min Suk ; Pascua, Philippe Noriel Q ; Kwon, Hyeok il ; Park, Su Jin ; Kim, Eun Ha ; Decano, Arun ; Kim, Se Mi ; Lim, Gyo Jin ; Kim, Doo Jin ; Chang, Kyu Tae ; Kim, Sang Hyun ; Choi, Young Ki. / Adjuvant efficacy of mOMV against avian influenza virus infection in mice. In: Journal of Microbiology. 2013 ; Vol. 51, No. 5. pp. 682-688.
@article{bde17557303a4ae7ab1075088cd24a08,
title = "Adjuvant efficacy of mOMV against avian influenza virus infection in mice",
abstract = "Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 103.5 EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.",
keywords = "avian influenza A virus, H5N2 vaccine, mOMV adjuvant",
author = "Lee, {Byeong Jae} and Lee, {Sang Ho} and Song, {Min Suk} and Pascua, {Philippe Noriel Q} and Kwon, {Hyeok il} and Park, {Su Jin} and Kim, {Eun Ha} and Arun Decano and Kim, {Se Mi} and Lim, {Gyo Jin} and Kim, {Doo Jin} and Chang, {Kyu Tae} and Kim, {Sang Hyun} and Choi, {Young Ki}",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/s12275-013-3411-3",
language = "English",
volume = "51",
pages = "682--688",
journal = "Journal of Microbiology",
issn = "1225-8873",
publisher = "Microbiological Society of Korea",
number = "5",

}

TY - JOUR

T1 - Adjuvant efficacy of mOMV against avian influenza virus infection in mice

AU - Lee, Byeong Jae

AU - Lee, Sang Ho

AU - Song, Min Suk

AU - Pascua, Philippe Noriel Q

AU - Kwon, Hyeok il

AU - Park, Su Jin

AU - Kim, Eun Ha

AU - Decano, Arun

AU - Kim, Se Mi

AU - Lim, Gyo Jin

AU - Kim, Doo Jin

AU - Chang, Kyu Tae

AU - Kim, Sang Hyun

AU - Choi, Young Ki

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 103.5 EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.

AB - Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 103.5 EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.

KW - avian influenza A virus

KW - H5N2 vaccine

KW - mOMV adjuvant

UR - http://www.scopus.com/inward/record.url?scp=84887867639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887867639&partnerID=8YFLogxK

U2 - 10.1007/s12275-013-3411-3

DO - 10.1007/s12275-013-3411-3

M3 - Article

C2 - 24173647

AN - SCOPUS:84887867639

VL - 51

SP - 682

EP - 688

JO - Journal of Microbiology

JF - Journal of Microbiology

SN - 1225-8873

IS - 5

ER -